Comprehensive review of chromophobe renal cell carcinoma.
Chromophobe renal cell carcinoma
Chromosomal aneuploidy
Immunotherapy
Mitochondrial gene mutations
Targeted therapy
Journal
Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
12
04
2020
revised:
27
11
2020
accepted:
27
02
2021
pubmed:
24
3
2021
medline:
21
4
2021
entrez:
23
3
2021
Statut:
ppublish
Résumé
Chromophobe renal cell carcinoma (chRCC) is the third most common type of RCC with distinct biology compared to other kidney cancer subtypes. The heterogeneity between the RCC subtypes is associated with noticeable differences in tumor aggressiveness and risk for the development of metastatic disease. ChRCC is characterized by chromosomal aneuploidy, TP53, PTEN, and mitochondrial gene mutations. Though the therapeutic landscape of clear cell RCC (ccRCC) has significantly evolved over the past decade, limited progress has been seen in chRCC due to its infrequent incidence. In fact, the therapeutic approach for chRCC is often extrapolated from ccRCC treatments or studies that combine several forms of nccRCC subtypes. In the new era of genetic profiling of tumors and targeted therapeutics, this review describes the epidemiology, pathology, molecular characteristics, and current management with ongoing clinical trials for chRCC.
Identifiants
pubmed: 33753250
pii: S1040-8428(21)00075-5
doi: 10.1016/j.critrevonc.2021.103287
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
103287Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.